Clinical efficacy of an anticolinergic agent in HAM/TPS patients with neurogenic bladder

Objective: To describe the efficacy of the propantheline bromide inneurogenic bladder in HTLV-I infected patients. Methods: From January/2001 to February/2004, twenty-one HTLV-I-carriers (7 men and 14 women)were selected for treatment with propantheline bromide 15 mg, PO, 2 to 3times a day for 3 mon...

Full description

Saved in:
Bibliographic Details
Published inEinstein (São Paulo, Brazil) Vol. 3; no. 4; pp. 251 - 254
Main Authors Néviton Matos de Castro, Daniel Meira Freitas, Waldyr Rodrigues Jr, Paulo Oliveira, André Muniz, Edgar Marcelino de Carvalho
Format Journal Article
LanguageEnglish
Published Instituto Israelita de Ensino e Pesquisa Albert Einstein 01.12.2005
Subjects
Bladder
Cholinergic antagonists
Human T-lymphotropic virus 1
neurogenic
Paraparesis
tropical spastic
Online AccessGet full text

Cover

More Information
Summary:Objective: To describe the efficacy of the propantheline bromide inneurogenic bladder in HTLV-I infected patients. Methods: From January/2001 to February/2004, twenty-one HTLV-I-carriers (7 men and 14 women)were selected for treatment with propantheline bromide 15 mg, PO, 2 to 3times a day for 3 months, not discontinuing in the follow-up. At the end ofthe treatment period, patients were revaluated through specificquestionnaires for urinary symptoms (UDI) and quality of life (Ditrovie).Results: From the 21 patients enrolled, 15 (71.4%) presented importantclinical improvement, referring decrease of urinary frequency, urgencyand loss, nocturia, and even total control of the dysfunction. Conclusion:We observed an efficient response to the anticholinergic agentpropantheline bromide in urinary dysfunction caused by the HTLV-I.
ISSN:1679-4508